NasdaqCM - Nasdaq Real Time Price USD

Delcath Systems, Inc. (DCTH)

5.66 +0.14 (+2.64%)
As of 10:01 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Gerard J. Michel MBA, MS CEO & Director 727.97k -- 1963
Ms. Sandra Pennell Senior VP of Finance and Principal Financial & Accounting Officer -- -- 1980
Dr. Martha S. Rook Ph.D. Chief Operating Officer -- -- 1970
Mr. David Hoffman General Counsel, Corporate Secretary & Chief Compliance Officer -- -- --
Dr. Johnny John M.D. Senior Vice President of Clinical Operations & Medical Affairs 472.16k -- 1965
Dr. Vojislav Vukovic M.D., Ph.D. Chief Medical Officer -- -- 1967

Delcath Systems, Inc.

1633 Broadway
22nd Floor Suite C
New York, NY 10019
United States
212 489 2100 https://www.delcath.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
76

Description

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Corporate Governance

Delcath Systems, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 10, 2024 - May 14, 2024
Delcath Systems, Inc. Earnings Call

Related Tickers

MYO Myomo, Inc.
3.5500
+3.20%
 
RCEL AVITA Medical, Inc.
8.95
+4.68%
 
TELA TELA Bio, Inc.
4.5500
-0.44%
 
CTSO Cytosorbents Corporation
0.8201
+1.25%
 
CLPT ClearPoint Neuro, Inc.
5.57
+1.00%
 
CATX Perspective Therapeutics, Inc.
1.5950
+4.25%
 
AXGN AxoGen, Inc.
7.01
+2.19%
 
CERS Cerus Corporation
1.7500
+3.55%
 
SNWV SANUWAVE Health, Inc.
0.0173
-19.53%
 
NARI Inari Medical, Inc.
37.76
-0.44%